|
1
|
Smith I and Chua S: Medical treatment of
early breast cancer. I: adjuvant treatment. BMJ. 332:34–37. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Early Breast Cancer Trialists’
Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal
therapy for early breast cancer on recurrence and 15-year survival:
an overview of the randomized trials. Lancet. 365:1687–1717.
2005.PubMed/NCBI
|
|
3
|
Bria E, Nistico C, Cuppone F, et al:
Benefit of taxanes as adjuvant chemotherapy for early breast
cancer: pooled analysis of 15,500 patients. Cancer. 106:2337–2344.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Buzdar AU, Singletary SE, Valero V, et al:
Evaluation of paclitaxel in adjuvant chemotherapy for patients with
operable breast cancer: preliminary data of a prospective
randomized trial. Clin Cancer Res. 8:1073–1079. 2002.PubMed/NCBI
|
|
5
|
Bontenbal M, Andersson M, Wildiers J, et
al: Doxorubicin vs epirubicin, report of a second-line randomized
phase II/III study in advanced breast cancer. EORTC Breast Cancer
Cooperative Group. Br J Cancer. 77:2257–2263. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jassem J, Pieńkowski T, Płuzańska A, et
al: Doxorubicin and paclitaxel versus fluorouracil, doxorubicin,
and cyclophosphamide as first-line therapy for women with
metastatic breast cancer: final results of a randomized phase III
multicenter trial. J Clin Oncol. 19:1707–1715. 2001.
|
|
7
|
Perez DJ, Harvey VJ, Robinson BA, et al: A
randomized comparison of single-agent doxorubicin and epirubicin as
first-line cytotoxic therapy in advanced breast cancer. J Clin
Oncol. 9:2148–2152. 1991.PubMed/NCBI
|
|
8
|
Bonneterre J, Dieras V, Tubiana-Hulin M,
et al: Phase II multicentre randomised study of docetaxel plus
epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide
in metastatic breast cancer. Br J Cancer. 91:1466–1471.
2004.PubMed/NCBI
|
|
9
|
Sledge GW, Neuberg D, Bernardo P, Ingle
JN, Martino S, Rowinsky EK and Wood WC: Phase III trial of
doxorubicin, paclitaxel, and the combination of doxorubicin and
paclitaxel as front-line chemotherapy for metastatic breast cancer:
an intergroup trial (E1193). J Clin Oncol. 21:588–592. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Paridaens R, Biganzoli L, Bruning P, et
al: Paclitaxel versus doxorubicin as first-line single-agent
chemotherapy for meta-static breast cancer: a European Organization
for Research and Treatment of Cancer Randomized Study with
cross-over. J Clin Oncol. 18:724–733. 2000.
|
|
11
|
Chan S, Friedrichs K, Noel D, et al:
Prospective randomized trial of docetaxel versus doxorubicin in
patients with metastatic breast cancer. J Clin Oncol. 17:2341–2354.
1999.PubMed/NCBI
|
|
12
|
Rha SY, Moon YH, Jeung HC, et al:
Gemcitabine monotherapy as salvage chemotherapy in heavily
pretreated metastatic breast cancer. Breast Cancer Res Treat.
90:215–221. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Spielmann M, Llombart-Cussac A, Kalla S,
et al: Single-agent gemcitabine is active in previously treated
metastatic breast cancer. Oncology. 60:303–307. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zelek L, Barthier S, Riofrio M, et al:
Weekly vinorelbine is an effective palliative regimen after failure
with anthracyclines and taxanes in metastatic breast carcinoma.
Cancer. 92:2267–2272. 2001. View Article : Google Scholar
|
|
15
|
Gasparini G, Caffo O, Barni S, Frontini L,
Testolin A, Guglielmi RB and Ambrosini G: Vinorelbine is an active
antiproliferative agent in pretreated advanced breast cancer
patients: a phase II study. J Clin Oncol. 12:2094–2101.
1994.PubMed/NCBI
|
|
16
|
Blum JL, Dieras V, Lo Russo PM, Horton J,
Rutman O, Buzdar A and Osterwalder B: Multicenter, Phase II study
of capecitabine in taxane-pretreated metastatic breast carcinoma
patients. Cancer. 92:1759–1768. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Blum JL, Jones SE, Buzdar AU, et al:
Multicenter phase II study of capecitabine in paclitaxel-refractory
metastatic breast cancer. J Clin Oncol. 17:485–493. 1999.PubMed/NCBI
|
|
18
|
Jassem J, Carroll C, Ward SE, Simpson E
and Hind D: The clinical efficacy of cytotoxic agents in locally
advanced or metastatic breast cancer patients pretreated with an
anthracycline and a taxane: a systematic review. Eur J Cancer.
45:2749–2758. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pivot XB, Li RK, Thomas ES, et al:
Activity of ixabepilone in oestrogen receptor-negative and
oestrogen receptor-progesterone receptor-human epidermal growth
factor receptor 2-negative metastatic breast cancer. Eur J Cancer.
45:2940–2946. 2009. View Article : Google Scholar
|
|
20
|
Ito Y, Osaki Y, Tokudome N, Sugihara T,
Takahashi S, Iwase T and Hatake K: Efficacy of S-1 in heavily
pretreated patients with metastatic breast cancer: cross-resistance
to capecitabine. Breast Cancer. 16:126–131. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Savio G, Laudani A, Leonardi V, Pepe A,
Scianna C, Gebbia V and Agostara B: Treatment of metastatic breast
cancer with vinorelbine and docetaxel. Am J Clin Oncol. 29:276–280.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Vici P, Di Lauro L, Sergi D, et al: A
phase II trial of docetaxel and vinorelbine in patients with
advanced breast cancer previously treated with anthracyclines.
Oncology. 75:175–181. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Albain KS, Nag SM, Calderillo-Ruiz G, et
al: Gemcitabine plus paclitaxel versus paclitaxel monotherapy in
patients with meta-static breast cancer and prior anthracycline
treatment. J Clin Oncol. 26:3950–3957. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chan S, Romieu G, Huober J, et al: Phase
III study of gemcitabine plus docetaxel compared with capecitabine
plus docetaxel for anthracycline-pretreated patients with
metastatic breast cancer. J Clin Oncol. 27:1753–1760. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
O’Shaughnessy J, Miles D, Vukelja S, et
al: Superior survival with capecitabine plus docetaxel combination
therapy in anthracycline-pretreated patients with advanced breast
cancer: phase III trial results. J Clin Oncol. 20:2812–2823.
2002.PubMed/NCBI
|
|
26
|
Oostendorp LJ, Stalmeier PF, Donders AR,
van der Graaf WT and Ottevanger PB: Efficacy and safety of
palliative chemotherapy for patients with advanced breast cancer
pretreated with anthracyclines and taxanes: a systematic review.
Lancet Oncol. 12:1053–1061. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kerbel RS and Kamen BA: The
anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer.
4:423–436. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Colleoni M, Rocca A, Sandri MT, et al:
Low-dose oral methotrexate and cyclophosphamide in metastatic
breast cancer: antitumor activity and correlation with vascular
endothelial growth factor levels. Ann Oncol. 13:73–80. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Colleoni M, Orlando L, Sanna G, et al:
Metronomic low-dose oral cyclophosphamide and methotrexate plus or
minus thalidomide in metastatic breast cancer: antitumor activity
and biological effects. Ann Oncol. 17:232–238. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wong NS, Buckman RA, Clemons M, et al:
Phase I/II trial of metronomic chemotherapy with daily dalteparin
and cyclophosphamide, twice-weekly methotrexate, and daily
prednisone as therapy for metastatic breast cancer using vascular
endothelial growth factor and soluble vascular endothelial growth
factor receptor levels as markers of response. J Clin Oncol.
28:723–730. 2010.
|
|
31
|
Nabholtz JM, Falkson C, Campos D, et al:
Docetaxel and doxorubicin compared with doxorubicin and
cyclophosphamide as first-line chemotherapy for metastatic breast
cancer: results of a randomized, multicenter, phase III trial. J
Clin Oncol. 21:968–975. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Miller K, Wang M, Gralow J, et al:
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic
breast cancer. N Engl J Med. 357:2666–2676. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fumoleau P, Largillier R, Clippe C, et al:
Multicentre, phase II study evaluating capecitabine monotherapy in
patients with anthracycline- and taxane-pretreated metastatic
breast cancer. Eur J Cancer. 40:536–542. 2004. View Article : Google Scholar : PubMed/NCBI
|
